14 stories mentioning SHA:600079Updated 1d ago
Every FINWIRES story that references SHA:600079, newest first.
Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for brexpiprazole tablets, according to a Shanghai bourse filing on Friday.The drug is used for the treatment of schizophrenia in adults.
Humanwell Healthcare's (SHA:600079) unit, Hubei Biomedical Industry Technology Research Institute, obtained approval from China's National Medical Products Administration for the clinical trial of HW243040 tablets, according to a Shanghai bourse filing on Wednesday.The drug is intended for the treatment of peripheral neuropathic pain.The pharmaceutical company's shares rose 2% during the midday trade.
Humanwell Healthcare (SHA:600079), through subsidiary RFSW Holding, agreed to sell its 16.34% equity in Lefusi Health Industry to Wuhan Hairun Biotechnology for 1.06 billion yuan, according to a Shanghai bourse filing on Wednesday.After the transaction, the pharmaceutical company will no longer hold any equity in Lefusi.The company's shares rose 2% during the midday trade.
Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, received registration certificates from China's National Medical Products Administration for carbamazepine extended-release capsules (II), according to a Shanghai bourse filing on Tuesday.The certificates, which are valid until July 20, 2031, cover the specifications of 100 milligrams, 200 mg and 400 mg.The drug is used for the treatment of epilepsy and trigeminal neuralgia.
Humanwell Healthcare's (SHA:600079) unit, Humanwell PuraCap Pharmaceuticals (Wuhan), received a drug registration certificate from China's National Medical Products Administration for its vinorelbine tartrate soft capsules, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's shares rose 1% during Monday's afternoon trade.The drug is used as a treatment for unresectable locally advanced or metastatic non-small cell lung cancer and metastatic breast cancer, either as monotherapy or in combination chemotherapy.
Humanwell Healthcare (SHA:600079) subsidiary Hubei Institute of Biomedical Industry Technology registered its phase 2 clinical trial for its HW211026 ointment for actinic keratosis, according to a Friday filing with the Shanghai bourse.Actinic keratosis is a precancerous skin lesion brought about by long-term chronic exposure to ultraviolet radiation.Cumulative research and development spending on the drug has so far reached 43 million yuan.
Humanwell Healthcare (SHA:600079) 80%-owned unit Yichang Renfu obtained the approval of China's drug regulator to conduct clinical trials for esketamine hydrochloride buccal mucosal solution.Under the trials, the drug will be tested for treating adult depression with acute suicidal ideation, according to a Friday filing on the Shanghai bourse.Shares of the pharmaceutical company declined 1% in recent trade.
China's drug regulator approved clinical trials by Humanwell Healthcare (SHA:600079) subsidiary Yichang Humanwell for the tapentadol hydrochloride oral solution.The drug is a pain reliever for children aged 2 years and older and for adults weighing more than 16 kilograms, according to a Tuesday filing with the Shanghai bourse.
China's drug regulator approved Humanwell Healthcare (SHA:600079) subsidiary Wuhan Humanwell Pharmaceutical's drug registration for its hydrocortisone sodium succinate injection.The injection is indicated for patients with toxic infections, anaphylactic shock, severe adrenocortical conditions, severe bronchial asthma and prevention of acute graft rejection, according to a Tuesday filing with the Shanghai bourse.
Humanwell Healthcare (SHA:600079) subsidiary RFSW Holding will divest 81.7 million shares in Lefusi Health Industry and list them in a property exchange for 1.06 billion yuan.The shares are equivalent to a 16.34% equity in the nursing facility services company, according to a Friday filing with the Shanghai bourse.
China's National Medical Products Administration accepted the marketing application of Humanwell Healthcare's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, for landiolol hydrochloride for injection, according to a Shanghai bourse filing on Thursday.The drug is used for the treatment of tachyarrhythmias in patients with heart failure or during surgery.The pharmaceutical company invested 9.5 million yuan into the research and development of the drug.
Humanwell Healthcare (SHA:600079) unit has secured U.S. Food and Drug Administration approval for its generic version of the fertility drug cetrorelix acetate injection.The injection is a fertility treatment used to prevent premature luteinizing hormone surges in women undergoing controlled ovarian stimulation, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company declined 1% in recent trade.
Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioidsShares of the pharmaceutical company declined 1% in recent trade.
Humanwell Healthcare (SHA:600079) attributable profit rose 8.9% to 588.2 million yuan in the first quarter from 540.3 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.Earnings per share at the drug company increased 9.1% to 0.36 yuan from 0.33 yuan in the prior-year period.Operating revenue slipped year over year to 6.10 billion yuan from 6.14 billion yuan.
